Overview Study of BHV-3241 in Subjects With Multiple System Atrophy Status: Active, not recruiting Trial end date: 2022-09-20 Target enrollment: Participant gender: Summary The purpose of this study is to compare the efficacy of BHV-3241 versus placebo in subjects with Multiple System Atrophy Phase: Phase 3 Details Lead Sponsor: Biohaven Pharmaceuticals, Inc.